According to a recent LinkedIn post from Truveta, the company’s research arm is highlighting a new analysis of estrogen-based hormone replacement therapy usage trends from 2018 to 2026. The post indicates that prescribing more than doubled over that period, with notable growth in patch and cream formulations and a marked increase among women ages 45–54.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests these patterns reflect broader shifts in menopause care, influenced by evolving clinical evidence, rising patient awareness, and recent U.S. FDA actions. It also points to a move away from oral therapies and underscores the role of real-world data in tracking adoption and practice changes, which may reinforce Truveta’s positioning as a data and analytics provider for healthcare and life sciences customers.
For investors, the emphasis on longitudinal prescription trends and real-world insights may signal growing demand for Truveta’s analytics capabilities among pharmaceutical, payer, and provider stakeholders. If the platform is increasingly used to understand therapy adoption and support regulatory and clinical decision-making, it could strengthen Truveta’s competitive standing in the health data analytics market and support future monetization opportunities.